• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Friday, October 24, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Psychedelic drug to be tested for treatment-resistant depression in Houston

Bioengineer by Bioengineer
October 8, 2019
in Health
Reading Time: 2 mins read
0
IMAGE
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

IMAGE

Credit: Photo by UTHealth


Psilocybin, a psychedelic drug believed to help rewire the brain, is now being studied to relieve treatment-resistant depression at The University of Texas Health Science Center at Houston (UTHealth) as part of a global Phase II clinical trial.

“It is a medication that can change or alter perceptions, cognition, thinking, and how minds see the environment,” said Sudhakar Selvaraj, MD, PhD, an assistant professor in the Faillace Department of Psychiatry and Behavioral Sciences at McGovern Medical School at UTHealth. “This therapy, if it works, could help at least a portion of people get relief from their depression and get back to day-to-day life.”

A 2012 study on the effects of psilocybin on the brain revealed that the drug may help create new circuits in the brain while potentially quieting others that may link to depression. Though the body will clear the drug in a matter of hours, the potential effects could last for several months or longer.

A previous study at Johns Hopkins University on the effects of the drug in cancer patients suggested that psilocybin therapy may lessen depressive symptoms. Psilocybin is broken down by the body to produce psilocin, which affects the serotonin system that regulates mood.

“It is not a drug that’s given to someone and then you just wait and see what happens. The therapists guide the patients through the experience after the administration of the medication,” Selvaraj said.

Participants in the double-blind study receive a single dose of the medication, either 25 mg, 10 mg or 1 mg. Neither the patient nor the study physician will know which dose participants are receiving. After taking the medication, patients are supervised by two therapists for eight hours in a specially designed, home-like, treatment room. Patients have preparation sessions with their therapists before the dosing day, and integration sessions afterwards.

Individuals participating in the trial will answer a questionnaire to measure depression symptoms the day before and the day after taking the single dose – and again one, three, six, nine and 12 weeks out.

Currently, psilocybin is a controlled Schedule 1 substance and is not approved in the U.S. to treat depression. However, the Food and Drug Administration has approved its use in this trial, and has designated this program of psilocybin therapy for treatment-resistant depression a Breakthrough Therapy.

To qualify, participants must be between the ages of 18 and 55 and have a diagnosis of treatment-resistant depression. Participants are being recruited in the Houston area.

###

For more information on this clinical trial, visit ClinicalTrials.gov, contact the UTHealth Center of Excellence on Mood Disorders at (713) 486-2627, or email [email protected].

Media Contact
Wendi Hawthorne
[email protected]
713-500-3030

Tags: BehaviorClinical TrialsCoping/PhobiasDepression/AngerMedicine/HealthMental HealthPerception/AwarenessPharmaceutical ScienceStress/Anxiety
Share12Tweet8Share2ShareShareShare2

Related Posts

New Brain PET Tracer Targets TDP-43 Pathology

October 24, 2025

Evaluating Chinese Nurses’ Sexual Harassment Scale Validity

October 24, 2025

Low-Dose Dienogest: 48 Weeks of Endometriosis Relief

October 24, 2025

Democratizing Protein Language Models: Training, Sharing, Collaborating

October 24, 2025
Please login to join discussion

POPULAR NEWS

  • Sperm MicroRNAs: Crucial Mediators of Paternal Exercise Capacity Transmission

    1279 shares
    Share 511 Tweet 319
  • Stinkbug Leg Organ Hosts Symbiotic Fungi That Protect Eggs from Parasitic Wasps

    308 shares
    Share 123 Tweet 77
  • ESMO 2025: mRNA COVID Vaccines Enhance Efficacy of Cancer Immunotherapy

    184 shares
    Share 74 Tweet 46
  • New Study Suggests ALS and MS May Stem from Common Environmental Factor

    133 shares
    Share 53 Tweet 33

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Rab5 GTPases Direct ROP Signaling for Pollen Polarity

New Brain PET Tracer Targets TDP-43 Pathology

Evaluating Chinese Nurses’ Sexual Harassment Scale Validity

Subscribe to Blog via Email

Success! An email was just sent to confirm your subscription. Please find the email now and click 'Confirm' to start subscribing.

Join 66 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.